Literature DB >> 27665525

Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients.

Adnan Abuhammour1, Asad Dajani2, Mohammed Nounou3, Mohammed Zakaria4.   

Abstract

BACKGROUND AND STUDY AIMS: Untreated Helicobacter pylori infection causes increased risk of gastric cancer, GI morbidity and mortality. Standard treatment for eradication of Helicobacter pylori infection, is the triple therapy which consists of a proton pump inhibitor; together with two antibiotics (amoxicillin 1000mg with clarithromycin 500mg or metronidazole 400mg) given twice daily for 7-14days. Recent evidence revealed, that cure rates of Helicobacter pylori infection with triple therapy had fallen below satisfactory targets. Sequential therapy consisting of a twice daily dose of a PPI for ten days with Amoxicillin given at 1000mg twice daily in the first 5days followed by clarithromycin 500mg and Metronidazole 400mg given twice daily in the subsequent 5days, was recommended to improve eradication rates. We performed a randomised open label study to compare the efficacy of sequential against triple therapy in Helicobacter pylori naive and retreat patients. PATIENTS AND METHODS: In a randomised open label observational study 485 patients fulfilling inclusion and exclusion criteria were randomly assigned to be treated with triple therapy (n=231) or sequential therapy (n=254). Eradication of Helicobacter pylori was documented with 14C Urea breath test (UBT) performed 6weeks after the treatment.
RESULTS: The intention-to-treat eradication rate was better in sequential therapy group 84.6% than triple therapy 68% (p<0.001). Eradication rates were significantly higher for treatment naive than retreat patients in triple therapy group (70.5% and 58.3%, respectively, p<0.01). A trend of a better response was observed in eradication rate for treatment naive 88.55% versus retreat 74.6% in sequential therapy group but was not statistically significant (p=0.76). Compliance was similar in the two groups, however side effects were less and the clinical response was better in the sequential therapy group.
Copyright © 2016 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clarithromycin resistance; H. pylori; Sequential; Triple therapy

Mesh:

Substances:

Year:  2016        PMID: 27665525     DOI: 10.1016/j.ajg.2016.07.001

Source DB:  PubMed          Journal:  Arab J Gastroenterol        ISSN: 1687-1979            Impact factor:   2.076


  5 in total

1.  Randomized Clinical Trial on the Efficacy of Triple Therapy Versus Sequential Therapy in Helicobacter pylori Eradication.

Authors:  Zain Sharif; Muaz Mubashir; Mehdi Naqvi; Hassan Atique; Saira Mahmood; Muneeb Ullah
Journal:  Cureus       Date:  2022-05-10

Review 2.  First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines.

Authors:  Vincenzo De Francesco; Annamaria Bellesia; Lorenzo Ridola; Raffaele Manta; Angelo Zullo
Journal:  Ann Gastroenterol       Date:  2017-06-01

3.  Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients.

Authors:  Libin Zhang; Ping Hu
Journal:  Clin Interv Aging       Date:  2017-04-12       Impact factor: 4.458

4.  Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study.

Authors:  Endalew Gebeyehu; Desalegn Nigatu; Ephrem Engidawork
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

5.  The cost-effectiveness of sequential versus standard triple therapy for Helicobacter pylori eradication in Saudi Arabia.

Authors:  Yazed AlRuthia; Majid A Almadi; Sadeem Alqahtani; Hala Alrasheed; Mohammad Al-Owairdhi; Fahad Alsohaibani
Journal:  Saudi J Gastroenterol       Date:  2021 Jul-Aug       Impact factor: 2.485

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.